Autolus Therapeutics (AUTL) Other Non-Current Assets (2018 - 2025)
Autolus Therapeutics posted quarterly Other Non-Current Assets of $249000.0 for Q4 2025, down 74.14% year-on-year from $963000.0 in Q4 2024, and up 30.37% on a QoQ basis from $191000.0 in Q3 2025.
Autolus Therapeutics (AUTL) has 8 years of Other Non-Current Assets data on file, last reported at $249000.0 in Q4 2025.
- For the quarter ending Q4 2025, Other Non-Current Assets fell 74.14% year-over-year to $249000.0; the trailing twelve-month figure through Dec 2025 stood at $249000.0 (down 74.14% YoY), and the FY2025 full-year result was $249000.0, down 74.14% from the prior year.
- Other Non-Current Assets for Q4 2025 stood at $249000.0, up from $191000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $5.3 million in Q2 2025 and bottomed at -$5000.0 in Q3 2022.
- The 5-year median for Other Non-Current Assets is $811000.0 (2021), against an average of $1.1 million.
- The widest annual swing landed in 2022, when Other Non-Current Assets sank 100.62%; it then jumped 18960.0% in 2023.
- A 5-year view of Other Non-Current Assets shows it stood at $2.4 million in 2021, then retreated by 7.87% to $2.2 million in 2022, then tumbled by 82.54% to $380000.0 in 2023, then jumped by 153.42% to $963000.0 in 2024, then slumped by 74.14% to $249000.0 in 2025.
- The last three Other Non-Current Assets figures came in at $249000.0 (Q4 2025), $191000.0 (Q3 2025), and $5.3 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 2.13 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Autolus Therapeutics | - | - | -1.04 Mn | 249,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 249,000.00 |
| Sep 30, 2025 | 191,000.00 |
| Jun 30, 2025 | 5.26 Mn |
| Mar 31, 2025 | 116,000.00 |
| Dec 31, 2024 | 963,000.00 |
| Sep 30, 2024 | 1.03 Mn |
| Jun 30, 2024 | 284,000.00 |
| Mar 31, 2024 | 975,000.00 |
| Dec 31, 2023 | 380,000.00 |
| Sep 30, 2023 | 943,000.00 |
| Jun 30, 2023 | 51,000.00 |
| Mar 31, 2023 | 465,000.00 |
| Dec 31, 2022 | 2.18 Mn |
| Sep 30, 2022 | -5,000.00 |
| Jun 30, 2022 | 1.89 Mn |
| Dec 31, 2021 | 2.36 Mn |
| Sep 30, 2021 | 811,000.00 |
| Jun 30, 2021 | 811,000.00 |
| Mar 31, 2021 | 1.84 Mn |
| Dec 31, 2020 | 2.63 Mn |
| Sep 30, 2020 | -455,000.00 |
| Jun 30, 2020 | 2.35 Mn |
| Mar 31, 2020 | -18,000.00 |
| Dec 31, 2019 | 2.04 Mn |
| Sep 30, 2019 | -724,000.00 |
| Jun 30, 2019 | -714,000.00 |
| Mar 31, 2019 | -707,000.00 |
| Dec 31, 2018 | 1.28 Mn |